Results 181 to 190 of about 36,256 (261)

A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

AstraZeneca
openalex   +1 more source

Predictors of overall survival in advanced biliary tract cancer in the phase 3 TOPAZ-1 study. [PDF]

Hepatol Commun
He AR, Bouattour M, Gupta VG, Evesque L, Zhen DB, Park JO, Sookprasert A, Salvatierra A, Vaccaro G, Oh SC, Ostoich SA, Satoh T, Kuzko A, Żotkiewicz M, Rokutanda N, Oh DY.   +15 more
europepmc   +1 more source

Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis. [PDF]

Front Oncol
Zhang H, Liu Y, Cai B, Wang M, Li H, Wang H.   +5 more
europepmc   +1 more source

Supplementary Figure S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial

Natalie Y.L. Ngoi, Chel Hun Choi, Junxian Zhu, Diana Lim, Tuan Zea Tan, Haoyang Sun, Valerie Heong, Samuel G.W. Ow, Wen Yee Chay, Hee Seung Kim, Yi Wan Lim, Siew Eng Lim, Geraldine Goss, Jeffrey C. Goh, Jae‐Weon Kim, Michael Friedländer, Bee Choo Tai, Kidong Kim, David S.P. Tan   +18 more
openalex   +1 more source

Investigation of non-completion factors for durvalumab maintenance therapy in locally advanced non-small cell lung cancer. [PDF]

Transl Lung Cancer Res
Kotake M, Sakai Y, Watanabe S, Kikuchi T, Toyama A.   +4 more
europepmc   +1 more source

Systematic review on the safety and efficacy of immune checkpoint inhibitors combined with stereotactic body radiotherapy in advanced pancreatic cancer. [PDF]

Clin Exp Med
Magashi MA, Danbala IA, Shaibu Z, Abdullahi MM, Cai H.   +4 more
europepmc   +1 more source

Durvalumab Is Associated with Prolonged Progression-Free Survival, While Concomitant Chemoradiotherapy May Improve Both Locoregional and Local Control in Elderly Patients with Unresectable NSCLC Stage III: Subanalysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). [PDF]

Med Sci (Basel)
Zehentmayr F, Karner J, Stana M, Ruznic E, Zellinger B, Klebermass M, Purevdorj A, Gruber G, Minasch D, Heilmann M, Moosbrugger R, Roeder F, Grambozov B.   +12 more
europepmc   +1 more source

Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial

V. Gounant, Laurent Greillier, Céline Mascaux, F. Pinquié, D. Carmier, L. Moreau, Benoît Roch, D. Debieuvre, X. Dhalluin, E. Giroux-Leprieur, E. Berton, Audrey Rabeau, Judith Raimbourg, A. Dixmier, Charles Naltet, Antoine Khalil, Lynn Ezzeddine, Mostafa El Hajjam, Alexandra Langlais, Franck Morin, Virginie Westeel, Gérard Zalcman, M. Duruisseaux   +22 more
openalex   +1 more source

P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC [PDF]

, 2019
John V. Heymach, Janis M. Taube, Tetsuya Mitsudomi, David Harpole, Mike Aperghis, Leonardo Trani, Mark Powell, Phillip A. Dennis, Martin Reck   +8 more
openalex   +1 more source

MLR and dMLR Predict Locoregional Control and Progression-Free Survival in Unresectable NSCLC Stage III Patients: Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). [PDF]

J Clin Med
Hochreiter A, Stana M, Klebermass M, Ruznic E, Grambozov B, Karner J, Heilmann M, Minasch D, Purevdorj A, Gruber G, Moosbrugger R, Röder F, Zehentmayr F.   +12 more
europepmc   +1 more source